Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT00490113

A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria

Effects of Pyridoxamine on Oxalate Excretion in Stone Disease and Hyperoxaluria

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
University of Kansas Medical Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

To determine whether pyridoxamine can decrease oxalate excretion in subjects who have normal oxalate excretion (but who have had kidney stones), and in subjects who have primary hyperoxaluria.

Conditions

Interventions

TypeNameDescription
DRUGPyridoxamineTwo 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.

Timeline

Start date
2007-01-01
First posted
2007-06-22
Last updated
2017-01-05

Source: ClinicalTrials.gov record NCT00490113. Inclusion in this directory is not an endorsement.

A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria (NCT00490113) · Clinical Trials Directory